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Abstract.
Background: Corticobulbar symptoms have been reported in all stages of Huntington’s disease (HD); aspiration pneumonia
associated with swallowing impairment has been identified as the most common cause of death. Whilst recent research has
described positive effects of corticobulbar rehabilitation in other neurodegenerative conditions, it is unclear if this is similarly
effective in HD. Preliminary evidence in corticospinal rehabilitation has revealed physical therapy and exercise could be
beneficial for individuals with HD.
Objective: This systematic review will explore the literature relative to rehabilitation of corticobulbar symptoms in adults
with HD.
Methods: Two investigators independently searched relevant electronic databases for literature related to corticobulbar
rehabilitation in HD, published in English until October 2019. Included studies were critically appraised using the Oxford
Centre for Evidence-based Medicine Levels of Evidence, Cochrane Risk of Bias Tool and Scottish Intercollegiate Guidelines
Network checklists. Study outcomes included measurements of function, quality of life or neuromuscular physiology.
Results: Seventy-seven publications were screened with eight studies meeting the inclusion criteria – two randomised control
trials and six intervention studies. Validated and objective outcome measures of corticobulbar symptoms were infrequently
used. There was a high risk of bias identified in 7/8 studies. The data suggested positive clinical outcomes, no adverse effects
and no deterioration observed across longitudinal studies.
Conclusions: This systematic review documented a lack of high-quality evidence to support the use of rehabilitation to
treat corticobulbar symptoms in HD. However, the suggestion of potential positive effects based on available, albeit limited,
studies provides justification for further research in this area.
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INTRODUCTION
Despite the recent progression in clinical trials and
pharmaceutical therapies to slow or alter the progres-
sion of Huntington’s disease (HD), there are currently
no effective medical treatments [1, 2]. It is there-
fore important to maximise proactive behavioural
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interventions to maintain function and improve
quality of life. The role of rehabilitation to treat neu-
rodegenerative diseases is a concept with emerging
evidence in several conditions, including HD [3–5].
The majority of individuals with HD will develop
corticobulbar symptoms [6]. These often present
as noticeable changes in speech (dysarthria) and
swallowing (dysphagia). Whilst these symptoms
may be primarily related to progressive cortical
neurodegeneration, evidence also highlights that
commonly prescribed anti-choreic medications have
side effects which include dysphagia, xerostomia (dry
mouth), dysarthria and drowsiness [7–9]. Corticobul-
bar impairments such as dysphagia and dysarthria are
highly correlated with decreased quality of life, inde-
pendence and increased care giver burden [10–14].
The impact of cognitive impairment and changes
in mood, combined with corticobulbar symptoms
affect the ability to communicate successfully and
participate in meaningful social interactions [15].
Dysphagic and dysarthric symptoms will be the key
focus of this review.
Oropharyngeal dysphagia and dysarthria have
been widely reported in all stages of HD [15–21].
Whilst these corticobulbar symptoms are highly
variable between individuals, there are identified
correlations between the severity of dysphagia,
dysarthria and disease progression [6, 22]. In HD,
all phases of swallowing can be impaired, impacted
by choreic movements, cognitive impairment and
behavioural changes [6]. Abnormal swallowing phys-
iology in HD compromises swallowing safety with
aspiration pneumonia reported as the leading cause
of death in this condition [23, 24]. In addition,
motor speech changes associated with HD can fall
into several dysarthria categories; however, fea-
tures of hyperkinetic dysarthria are most commonly
described in the literature [25, 26]. Speech in HD is
typically characterised by rapid involuntary move-
ments of respiration, phonation, and articulation
impacting on speech production, prosody and res-
onance [15, 21, 27]. Many people are unable to
communicate effectively at the end stages of the
disease.
In recent years, there has been an increase in
studies evaluating corticospinal rehabilitation and
exercise for individuals with HD [28–31]. Physical
therapy and exercise interventions were reportedly
well tolerated, resulting in measurable improvement
in function during daily activities, cognition and self-
reported quality of life [29, 30, 32]. Bilney et al. [5]
also reported some functional improvements in gait
and balance following multidisciplinary interven-
tions in individuals with HD. European Huntington’s
Disease Network Physiotherapy Guidelines have rec-
ommended targeted behavioural treatment for people
in early to mid-stage HD to improve or maintain
functional ability [33]. These guidelines reflect best
available evidence and suggest no detrimental effects
of intensive behavioural interventions.
This emerging evidence highlights the importance
of behavioural interventions and exercise combined
with pharmaceutical therapies in the long-term man-
agement of HD. An active rehabilitative approach
to target corticospinal symptoms has been described
as a crucial part of individual HD management
[8, 30, 34]; however, the efficacy of rehabilitation
targeting corticobulbar symptoms has not yet been
reviewed. Compensatory strategies are most com-
monly applied to manage dysarthria and dysphagia
as active rehabilitation has historically been assumed
to be detrimental in neurodegenerative populations
[3]. Importantly, a careful review of the literature
in amyotrophic lateral sclerosis reveals insufficient
evidence to suggest that moderate-intensity reha-
bilitative approaches are contraindicated in this
neurodegenerative population [3]. Thus, the present
review was conducted to explore the literature relative
to rehabilitation of corticobulbar symptoms in adults
with HD. This then forms the foundation for future
research aimed to maintain or improve corticobulbar
function in HD.
MATERIALS AND METHODS
The methodology for this review was regis-
tered with the International Prospective Register
of Systematic Reviews (PROSPERO registration
number: CRD42017064156) and aligned with Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. Two investi-
gators independently searched electronic databases
for published literature in English until October
2019 using Medline-Ovid, Embase-Ovid, CINAHL,
Web of Science (science and social science cita-
tion index), Science Direct, Scopus, Pubmed, The
Cochrane Library (Cochrane Database of System-
atic Reviews), clinical trial registers and best practice
guidelines. The search strategy firstly identified the
appropriate MeSH terms using the ‘map to MeSH
term’ function in the Ovid version on Medline. This
process was then repeated for each bibliographic
database and relevant papers were screened for
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additional MeSH terms. These key words were then
included in the subsequent literature searches. Key
words used were: Huntington, Huntington’s disease,
Huntington’s chorea, dysphagia, deglutition, bulbar,
swallowing, speech, dysarthria, motor speech, artic-
ulation disorders, treatment and rehabilitation. All
selected studies were manually cross-referenced to
ensure no relevant literature was missed. The search
was repeated prior to the final analysis. Abstracts,
and then full articles, were reviewed collaboratively
to compile a final list for review.
Studies met the inclusion criteria if they evaluated
intervention with adults with manifest Huntington’s
Disease, who had reported Shoulson & Fahn Stag-
ing 1–5, or presence of ≥36 CAG trinucleotide
expansion repeats confirmed via genetic testing [35].
Articles with Juvenile HD (JHD) participants were
not included as the significantly higher CAG repeats
reported in JHD often result in more severe early
cognitive and behavioural impairment, as well as
faster disease progressions. Articles were included
if they aimed to result in long term changes in
the underlying neuromuscular substrates that present
as corticobulbar symptoms in HD. This included
interventions targeting the corticobulbar pathway.
Specifically, direct innervation to cranial nerves III,
IV, V, VI, VII, IX, X, XII or the muscles of the
face, tongue, jaw, pharynx, head and neck. Sensory
interventions that aimed to rehabilitate the corticobul-
bar pathway were also included. Literature excluded
from this review were any interventions that focussed
solely on compensatory strategies in isolation, such as
modified diets, utensil modification, increased super-
vision.
Data extracted from the studies were grouped,
compared and summarised using structured narrative
(descriptive) analyses including specific population
(e.g. stage of Huntington’s disease), intervention
content, intervention effects and outcome measures
where possible. Included studies were critically anal-
ysed using the Scottish Intercollegiate Guidelines
Network (SIGN) Algorithm and Critical Appraisal
Checklists [36, 37]. Levels of evidence were rated
according to Oxford Centre for Evidence-based
Medicine Levels of Evidence [38] and risk of bias
was judged using the Cochrane Risk of Bias Tool
[39, 40].
RESULTS
In total 888 publications were identified. As
detailed in the PRISMA flowchart (Fig. 1), 77 full
text articles were reviewed, 19 studies were excluded
as they described compensatory management only.
Of the remaining 58, only eight studies matched
the inclusion criteria: two randomised control tri-
als (RCTs) and six intervention studies evaluated
rehabilitative approaches to improve corticobulbar
symptoms. It is acknowledged that one of the RCTs
evaluated rehabilitation of olfactory (CN I) function,
which is not specifically included in the corticobul-
bar pathways [41]. This study was included given
potential impact of olfaction on other corticobulbar
symptoms in HD. See Table 1 for a summary of
included studies. Using the SIGN Algorithm [36],
only two studies were rated as appropriate to assess
quality of evidence using the SIGN Critical Appraisal
Checklists (see the Supplementary Material) [37].
The remaining studies were critically analysed using
the Cochrane Risk of Bias Tool, and descriptively
reviewed below. Quantitative data synthesis was not
possible as the low yield of articles used varied out-
come measures and therefore were not sufficiently
homogenous.
Descriptive analysis of key study features
Study design
Table 1 outlines the study designs that were used
to evaluate the effectiveness of rehabilitation in
individuals with HD. Two studies were RCTs and
adopted control groups who received sham treatment
[41, 42]. The remaining five studies were within-
subject intervention case series/cohort studies [13,
43–46]. Participants were assessed pre- and post-
intervention. One of these inpatient study designs
then used a non-standardised questionnaire mailed to
participants who had completed the first rehabilitative
study [13].
Participants
Treatment groups ranged from five [46] to 40 [43]
participants who completed corticobulbar interven-
tions. All studies included individuals at varying
stages of the disease which limits comparison of
rehabilitation approaches. The Unified Huntington’s
Disease Rating Scale (UHDRS) was used in two stud-
ies to characterise the stage and severity of the disease
[42, 46]. Subcategories of this scale were also used
as outcome measures in two other studies [44, 45].
One study included only individuals with mild HD
(Stage 1 or 2 according to the UHDRS) [46]. The
majority of studies included participants with mild-
moderately advanced HD [13, 43–45], whilst Leng
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Fig. 1. PRISMA Flowchart for identifying studies for systematic review.
et al. [41] included only late-stage (stage 5) HD in
their recruitment.
Setting of therapy
Intervention took place in a variety of settings and
with different service delivery models. Four studies
took place in inpatient facilities and included MDT
rehabilitation [13, 43–45], one in a specialist residen-
tial home [41], two were home-based programmes of
daily exercises [42, 46] and one was in an unspeci-
fied outpatient clinic [47]. All studies reported good
adherence to therapy programmes and participation
in intervention across settings; however, no system-
atic measurements of adherence were reported.
Intervention
Interventions to maintain or improve speech and
swallowing were intensive; six studies evaluated
daily intervention [13, 43–46], one completed ses-
sions twice per week [41], and one stated that 11/12
patients were “intensively treated” but did not specify
what this consisted of [page 59, 47]. Where specified,
the duration of intervention ranged from three weeks
[13, 43–45] to four months [42]. Giddens et al. [46]
reported that oral motor labial and lingual resistance
training, respiratory (glottal adduction) and phona-
tory exercises were completed twice daily at home,
a minimum of four times per week for 30 days. The
number of participants that fully adhered to the long-
term exercise program was not reported. Similarly,
Reyes et al. [42] evaluated inspiratory and expira-
tory muscle training using a home programme of six
training sessions per week for four months. The train-
ing group received increased resistance to respiratory
pressures over the course of treatment, whilst the con-
trol group received a sham protocol with the same
device. There were no adverse effects of intensive
training and all participants adhered to the protocol,
but it is not reported if the adherence to the home
programme was specifically measured [42].
Four studies evaluated interventions to maintain
or improve speech and swallowing function as part
of an intensive inpatient MDT approach [13, 43–45].















Summary of 8 studies included in this systematic review of corticobulbar rehabilitation in adults with Huntington’s disease
Author Participants Study Design & Level of
Evidence
Treatment Outcome Measures Results/conclusions
Leopold & Kagel [47] N = 12, 11 moderate HD, 1
mild-moderate HD.

















returned to a normal diet.
3/11 minimally restricted
diet. Maintained for 3
years.
Leng et al. [41] N = 12, mid-late HD in a
specialised residential unit.
(2 withdrawn with medical
complications)
Randomised controlled pilot

























Zinzi et al. [43] N = 40, mild-moderate HD
(25 completed study)
Pilot study (2b) Individual and group
intervention (PT, OT &
SLT) in an inpatient
rehabilitation facility. 3
week block of intensive
treatment. Treatment block
could be repeated 3 times a
year. 8 hours of
intervention per day 5
times a week, 4 hours for 1







Each 3 week block of
treatment resulted in highly
significant (p > 0.001)
improvements in motor
performance and activities
of daily living. No
carry-over effect from one
admission to the next but
no motor decline was
detected over two years.
Dysarthria and dysphagia
specific measurement in


















Author Participants Study Design & Level of
Evidence
Treatment Outcome Measures Results/conclusions
Zinzi et al. [13] N = 40 who had completed at












also conducted on written
texts.
Improvements were reported





p < 0.05). Improvements in
gait, balance, motor
control, and fall reduction
were also described.
Duration of benefits
estimated to last 1–3
months by 71% of
informants with no carry
over to the next admission.
Giddens et al. [46] Case series: N = 14 13 early
HD, 1 late HD Pilot study:
N = 7, early HD (5
completed study)
Case study & Pilot study (4) Home-based oral motor,
phonatory and respiratory
exercises.







cranial nerve function and
phonation time.
Piira et al. [44] N = 37, early-mid stage HD
(31 completed study)
Intervention study (2b) Daily 1:1 or group therapy






exercises at least 3 times




training. 3 week block of
intensive treatment.
Treatment block could be
repeated 3 times a year.
MMSE and Unified HD
Rating Scale.
Motor Function: 6min
walking test, TUG, 10m




Anxiety Scale, Quality of
Life SF 12 questionnaire.
Significant improvements in
gait function, balance,




decline in only one
cognitive measure
(SDMT). No other decline.
Dysarthria and dysphagia
specific measurement in
Barthel Index were not
stated.
















































































































































































































































































































































































































































































































































































intervention which focused on physical exercise,
social activities, and family/caregiver education
teaching sessions [44, 45]. SLT intervention was
reported, but specific dysarthria and dysphagia exer-
cises were not described in any of the MDT studies,
thus inhibiting replicability. Zinzi et al. [43] included
non-specified speech therapy where patients were
“taught strategies for swallowing” [page 40, 42]
amongst other MDT intervention. This study also
completed respiratory exercises using visual and
tactile feedback during joint sessions with the phys-
iotherapist and SLT [43].
Leopold et al. [47] provided a description of
their dysphagia intervention which included a modi-
fied Valsalva manoeuvre (forced exhalation against
a pinched nose) alongside compensatory strate-
gies (diet modification, adaptive utensils, optimum
positioning). Patients were taught the ‘chew-
swallow-cough-swallow sequence’ technique. An
unspecified number of the twelve participants with
severe dysphagia required non-oral feeding to main-
tain nutrition and hydration via nasogastric tube
until the “compensatory techniques could be insti-
tuted and a pureed diet could be safely tolerated”
[page 59, 47]. The authors stated that “more severely
demented patients required more sessions” [page 60,
47] and greater ongoing supervision post-therapy to
target more severe cognitive and motor sequencing
deficits; however, this additional therapy was not
clearly defined. The duration of the intervention was
not stated, and the results were not statistically anal-
ysed.
Leng et al. [41] did not focus on dysarthria or
dysphagia intervention. Instead, this study measured
the effect of multisensory environmental stimula-
tion (MSE) compared to passive relaxation therapy.
The standardised MSE intervention was designed
for visual, tactile, auditory and olfactory innerva-
tion. The authors described the specific intervention
sufficiently to allow for replication.
Outcome measures
All intensive MDT intervention studies included
broad outcome measures of motor performance
(including walking, gait, and balance), ratings of
ability to perform activities of daily living (ADL),
cognitive measures (typically the Mini-Mental State
Examination and UHDRS) and quality of life mea-
sures [13, 43–45]. No instrumental or objective
measures of speech or swallowing were reported
in these studies; however, the Barthel Index (a
measure of ADL) includes questions about feeding
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independence and diet modification. Piira et al. [45]
used these baseline measures to report no functional
decline in cognition, ADL, gait or balance in partic-
ipants who continued the rehabilitation programme
for another year after initial admission. Zinzi et al.
[43] also used the Physical Performance Test (PPT)
to measure the functional speed and accuracy of spe-
cific tasks. This standardized test included a measure
of functional eating. The authors reported significant
positive treatment effects on motor and functional
performance as measured by the PPT and Tinetti
Scale. This improvement was not retained between
inpatient admissions. The authors highlighted an
overall lack of decline in other cognitive and func-
tional measures such as the Barthel Index over the
two year follow up period [43].
Many studies included subjective or non-
standardised measures of corticobulbar symptoms.
Giddens et al. [46] used an unspecified swallowing
screening with no instrumental assessment or func-
tional outcome measures. They reported significant
improvements post-therapy on subjective oral motor
ratings and diadochokinetic ratings. Two of the six
participants self-reported an ‘elimination’ of their
swallowing impairment post-therapy, but there were
no objective measures of this. Conversely, Leopold
et al. [47] described several objective assessments of
swallowing including videofluoroscopic swallowing
studies, oesophageal manometry, pulmonary func-
tion testing, mealtime observation and neurological
examination. All participants demonstrated clinical
abnormalities of swallowing, speech and voluntary
coughing. Each participant was rated on a non-
standardised dysphagia severity scale (0 – 5) using
instrumental assessment findings. Videofluoroscopic
assessment was the only outcome measure repeated
post-therapy and was reported descriptively by the
authors. No objective timing or displacement mea-
sures were used to analyse the videofluoroscopic
studies. The study reported that all participants
improved and 73% (n = 8) returned to normal diet; the
remaining three were advised to have minimal diet
restrictions. These improvements were maintained
for up to 3 years post-treatment. This was inferred
as none of the participants required supplementary or
additional non-oral nutrition; however, no objective
follow up assessments were reported.
Reyes et al. [42] used spirometry measures of
inspiratory and expiratory pressures pre- and post-
treatment. A non-standardised version of the timed
water swallowing test was used to measure func-
tional swallowing ability with thin fluids. Participants
were instructed to drink 50mls of water three times
in each assessment session. The standardised Timed
Water Swallow Test is 150mls of water consumed
“as fast as is comfortably possible” [48]. Time per
swallow, swallowing capacity and volume improved
at two months and four months of training. Swal-
lowing related quality of life (SWAL-QoL) improved
slightly after four months of training. This study did
not include any objective or instrumental measures of
swallowing biomechanics. The treatment group had a
moderate training effect on maximum inspiratory and
expiratory pressures after four months of training. A
small effect was also reported for the control group.
Improvements were also noted in spirometry mea-
sures compared to the control group; however, these
differences were not statistically significant. Non-
significant improvements were also reported across
swallowing measures, including the adapted timed
water swallowing test. No studies included secondary
information regarding pulmonary status, rate of chest
infection or aspiration pneumonia.
As previously discussed, Leng et al. [41] focused
on a multisensory environment to evaluate the effects
of visual, tactile, auditory and olfactory stimulation.
This study did not include any direct measurements of
corticobulbar function, instead the primary measures
were of mood and behaviour using the Rehabilitation
Evaluation and Behaviour and Mood Disturbance rat-
ing scales. Physiological measures including heart
rate, respiratory flow and involuntary movements
(using the dyskinesia section of the St. Hans Rating
Scale) were collected throughout the 12 week obser-
vation period. The reliability and validity of these
outcome measures were not discussed, particularly
in relation to assessment of people with HD. The
researchers found an immediate effect of intervention
on mood during MSE sessions, and stimulation level
over time compared to the control group, but these
effects did not generalise between sessions. There
were no other significant differences between groups
in respect to involuntary movements or other mea-
sures. Although speech and swallowing symptoms
were not included in this RCT, this study evaluated a
rehabilitation which partially targeted olfactory (CN
I) function. This study was considered relevant to
include to reflect its impact on other corticobulbar
symptoms in HD.
Risk of bias
A summary of the Cochrane Risk of Bias Tool com-
pleted for each study is provided in Table 2. Low risk
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Table 2
Summary of Cochrane Risk of Bias Tool evaluation. H, high risk of bias, L, low risk of bias, U/C, unclear risk of bias
Sequence Allocation Blinding Outcome ax Incomplete Selective Other
generation concealment (pts/researchers) blinding data reporting bias
Leopold & Kagel [47] N/A N/A N/A H H H H
Leng et al. [41] L L H H L L U/C
Zinzi et al. [43] N/A N/A N/A U/C H L U/C
Zinzi et al. [13] N/A N/A N/A H L H H
Giddens et al. [46] N/A N/A N/A H H H H
Piira et al. [44] N/A N/A N/A H H L U/C
Piira et al. [45] N/A N/A N/A H H L U/C
Reyes et al. [42] L L U/C U/C L L U/C
of attrition bias was identified in 3/8 of studies [13,
41, 42], where complete outcome data were reported.
Additionally, there was low risk of bias in selective
reporting in 5/8 of studies [41–45]. The method of
data collection adopted by Zinzi et al. [13] was judged
to have a high risk of bias. Their non-standardised
questionnaire was mailed to participants on aver-
age 8.6 months post-intervention. This questionnaire
asked about their inpatient rehabilitation and care
experience; 91.9% (n = 34) of respondents were care-
givers and 8.1% (n = 3) respondents were patients
who had completed the inpatient intervention. This
method of data collection may have introduced a
recruitment bias and selective reporting as people
generally reported positive improvements on this sub-
jective questionnaire.
Giddens et al. [46] excluded participants with more
severe cognitive or motor impairments creating a risk
of selection bias. One participant with late (stage 4)
HD was withdrawn from the study as she subjec-
tively perceived increased muscle weakness with the
exercise program, however, there were no clinical
measures of this. Two participants changed their drug
regimens during treatment which created an addi-
tional variable. Whilst Leopold et al. [47]’s landmark
study published in 1985 is frequently referenced to
describe dysphagia in HD, the adopted study design
is vulnerable to several identified biases. Blinding of
raters was not possible, outcome measures were not
validated, or consistently repeated post-therapy. In
addition, data analysis of quantitative outcome mea-
sures was not conducted.
Both RCTs included in this review were deemed
low risk of bias in several domains [41, 42]. The
authors provided a detailed protocol for randomisa-
tion and intervention, including baseline and follow
up periods to measure any treatment effect. These
study designs were replicable and reduced risk of
bias, despite the small sample size. Leng et al. [41]
used two investigators to facilitate and score the
sessions, with good inter-rater reliability reported;
however, with this design blinding was not possi-
ble. Two participants withdrew from this study due
to medical complications which may have increased
selection bias, and significant changes in medication
were reported for two participants during the study,
introducing an additional variable. The other RCT
excluded those with moderate-severe corticobulbar
symptoms such as lingual chorea and oral weakness
which may have introduced a selection bias [42].
DISCUSSION
Historically, SLT management of HD focused on
compensation for speech and swallowing impair-
ment with approaches such as diet modification,
increased supervision, postural changes, stabilising
the mandible, and visual cues [47, 49]. Indeed, within
the screened literature, 17 articles did not meet the
inclusion criteria as they only described compen-
satory management of dysphagia and dysarthria.
Whilst these strategies may be important to imple-
ment as the disease progresses, it may be worth
considering the potential for rehabilitation, particu-
larly for treatment of dysphagia and dysarthria.
This systematic review revealed a lack of high-
quality evidence to justify the effectiveness of
rehabilitation for corticobulbar symptoms in HD.
Despite this, the included studies highlighted pre-
liminary evidence of potential benefits of ongoing
research regarding rehabilitation for corticobulbar
symptoms, such as dysphagia and dysarthria. Impor-
tantly, there was no significant deterioration observed
across longitudinal studies, which could be clinically
significant in this neurodegenerative disease. This
conclusion may be taken cautiously given that the
full trajectory of disease progression is not known;
however, with a study duration of up to three years,
it suggests at the very least, a possible short-term
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positive impact [13, 43–45, 47]. Further investiga-
tion into the effectiveness of specific rehabilitative
approaches is warranted as five of the included stud-
ies failed to describe which dysarthria or dysphagia
interventions were used [13, 43–45, 47]. Of the
interventions described in three studies, there was
inadequate homogeneity to allow for comparison
between rehabilitation methods [41, 42, 46].
In HD, corticobulbar deficits are not isolated to
muscle weakness [10, 49]. An alternative approach
may be to focus on optimising precision of neuromus-
cular connections instead of primarily compensatory
management. Giddens et al. [46] hypothesised that
the significant improvement observed in cranial nerve
function following intensive rehabilitation may be
attributed to better control and coordination of the
muscle groups integral to speech and swallowing.
Task specific rehabilitation based on the principles
of motor learning may be beneficial in HD man-
agement; as these intensive rehabilitative approaches
have shown potential to increase neuroplasticity and
cortical excitability [50, 51]. Structured rehabilita-
tive programmes which intensively target dysarthria
or dysphagia such as Lee Silverman Voice Treat-
ment, expiratory muscle strength training (EMST)
and video-assisted swallowing (VAS) therapy have
been evaluated in other neurodegenerative diseases.
Studies evaluating these rehabilitative approaches
have reported benefits following treatment to main-
tain or improve function in conditions such as
amyotrophic lateral sclerosis, multiple sclerosis and
Parkinson’s disease, [42, 52–55]. As Reyes et al.
[42] evaluated the effects of a structured EMST pro-
tocol in HD, this small RCT provided preliminary
evidence to suggest this muscle strengthening inter-
vention may be beneficial in HD. This justifies further
research into task specific skill-based interventions
and muscle strengthening approaches with larger
sample sizes and instrumental swallowing outcome
measures.
This review also highlighted the lack of objective
outcome measures used to evaluate therapy. Only one
study included the gold standard videofluoroscopic
swallowing studies pre- and post-therapy [47]. How-
ever, this study did not include standardised timing or
displacement measures of swallowing biomechanics.
Whilst one study included a swallowing specific qual-
ity of life questionnaire [42], the remaining studies
included non-standardised or nonspecific measures
of corticobulbar function. The omission of valid
and reliable outcome measures is problematic for
replicability and evaluation of treatment effects. Fur-
thermore, seven of the eight studies were judged to
have a high risk of bias identified in at least one cat-
egory (Table 2). As often seen in the wider literature
of this rare neurodegenerative disease, small sam-
ple sizes and underpowered studies were identified
as limitations in the majority of the studies included
in this review (Table 1). Whilst the disease stage or
UHDRS scores were described in most studies, other
key participant information such as level of cogni-
tion, medication regimes, or presence of depression
was not specified consistently.
Although the number of studies is limited and
the outcome measures lack objectivity, overall the
included studies suggested no adverse effects, and at
least the possibility of potential benefits of intensive
rehabilitation to improve or maintain function. The
therapy programmes were reportedly well adhered
to, with minimal withdrawal from intervention and
no measurable detrimental effects of an intensive
approach across several stages of the disease. This is
in line with systematic reviews evaluating corticob-
ulbar rehabilitation in other neurological populations
[3]. In addition, this echoes the findings of sys-
tematic reviews specifically focused on corticospinal
rehabilitation and exercise in HD [5, 29, 32, 33].
These reviews highlight the concept that rehabilita-
tive approaches may be beneficial in HD, counter to
traditional belief that active rehabilitation may not be
effective or tolerated in neurodegenerative diseases
[5]. Conversely, there has been a notable increase in
interest and literature since 2003 which has provided
evidence to support the feasibility and effectiveness
of early MDT intervention to maintain or improve
function in corticospinal symptoms of HD. This
valuable research may inform further development
of rehabilitative approaches to target corticobulbar
symptoms such as dysarthria and dysphagia.
Conclusion
There was not sufficient evidence to justify reha-
bilitation of corticobulbar symptoms on HD. The
best available research in early to mid-stage HD
suggested short-term improvements in motor func-
tion and quality of life following intensive functional
rehabilitation. However, there was no evidence of
detrimental effects from the available studies. The
existing evidence was limited by the risk of bias,
with a lack of valid and reliable objective tools
used. There was, however, sufficient preliminary evi-
dence to justify further research in this area using
well designed intervention studies with standardised,
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objective outcome measures to evaluate rehabilita-
tive approaches targeting corticobulbar symptoms in
individuals with HD.
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Oxman AD, et al. The Cochrane Collaboration’s tool for
assessing risk of bias in randomised trials. BMJ. 2011;343:
d5928.
[40] Higgins JPT, Green S. Cochrane Handbook for Systematic
Reviews of Interventions The Cochrane Collaboration2011
[Version 5.1.0 [Available from: http://www.handbook.coch
rane.org.
[41] Leng TR, Woodward MJ, Stokes MJ, Swan AV, Wareing L-
A, Baker R. Effects of multisensory stimulation in people
with Huntington’s disease: A randomized controlled pilot
study. Clin Rehabil. 2003;17(1):30-41.
[42] Reyes A, Cruickshank T, Nosaka K, Ziman M. Respira-
tory muscle training on pulmonary and swallowing function
in patients with Huntington’s disease: A pilot randomised
controlled trial. Clin Rehabil. 2015;29(10):961-73.
[43] Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni
S, Bentivoglio A, et al. Effects of an intensive rehabilitation
programme on patients with Huntington’s disease: A pilot
study. Clin Rehabil. 2007;21(7):603-13.
[44] Piira A, Van Walsem MR, Mikalsen G, Nilsen KH, Knutsen
S, Frich JC. Effects of a one year intensive multidisciplinary
rehabilitation program for patients with Huntington’s dis-
ease: A prospective intervention study. PLoS Curr. 2013;5.
[45] Piira A, Van Walsem MR, Mikalsen G, Øie L, Frich JC,
Knutsen S. Effects of a two-year intensive multidisciplinary
rehabilitation program for patients with Huntington’s dis-
ease: A prospective intervention study. PLoS Curr. 2014;6.
[46] Giddens CL, Coleman AE, Adams CM. A home program
of speech therapy in Huntington’s disease. J Med Speech
Lang Pathol. 2010;18(2):1-11.
[47] Leopold NA, Kagel MC. Dysphagia in Huntington’s dis-
ease. Arch Neurol. 1985;42(1):57-60.
[48] Hughes TA, Wiles CM. Clinical measurement of swal-
lowing in health and in neurogenic dysphagia. Q J Med.
1996;89(2):109-16.
[49] Kagel MC, Leopold NA. Dysphagia in Huntington’s dis-
ease: A 16-year retrospective. Dysphagia. 1992;7(2):106-
14.
[50] Athukorala RP, Jones RD, Sella O, Huckabee M-L. Skill
training for swallowing rehabilitation in patients with
parkinson’s disease. Arch Phys Med Rehabil. 2014;95(7):
1374-82.
[51] Herman T, Giladi N, Hausdorff J. Treadmill training for the
treatment of gait disturbances in people with Parkinson’s
disease: A mini-review. J Neural Transm. 2009;116(3):307-
18.
[52] Plowman EK. Impact of expiratory strength training in amy-
otrophic lateral sclerosis expiratory training in ALS. Muscle
Nerve. 2016;54(1):48-53.
[53] Troche M, Okun M, Rosenbek J, Musson N, Fernandez H,
Rodriguez R, et al. Aspiration and swallowing in parkinson
disease and rehabilitation with EMST A randomized trial.
Neurology. 2010;75(21):1912-9.
[54] Chiara T, Martin AD, Davenport PW, Bolser DC. Expiratory
muscle strength training in persons with multiple sclerosis
having mild to moderate disability: Effect on maximal expi-
ratory pressure, pulmonary function, and maximal voluntary
cough. Arch Phys Med Rehabil. 2006;87(4):468-73.
[55] Manor Y, Mootanah R, Freud D, Giladi N, Cohen JT. Video-
assisted swallowing therapy for patients with Parkinson’s
disease. Parkinsonism Relat Disord. 2013;19(2):207-11.
